Drug Search Results
More Filters [+]

Diatrizoate sodium

Alternative Names: diatrizoate sodium, md-50, urovist sodium 300, hypaque sodium 20%, gastrografin, angiovist 292, hypaque, renocal-76, hypaque-m,90%, renografin-76, md-76r, md-gastroview, hypaque-m,75%, diatrizoate-60, md-60, renovist ii, hypaque-76, renovist, md-76, angiovist 370, renografin-60, gastrovist, md gastroview
Latest Update: 2024-05-08
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Brazil | Chile | Colombia | Croatia | Cyprus | Dominican Republic | Egypt | Germany | Hong Kong | Hungary | India | Ireland | Italy | Malaysia | Malta | New Zealand | Norway | Pakistan | Peru | South Africa | Spain | Taiwan | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diatrizoate sodium

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events